Background
Sentinel lymph node (SLN) is the first node in the lymphatic system to receive lymphatic drainage [
1]. Sentinel lymph node biopsy (SLNB) has become a standard surgical technique in the management of early invasive breast cancer patients with clinically negative lymph node as it can reduce postoperative morbidity compared with axillary lymph node dissection [
2].
However, the lymphatic drainage of the breast has not been studied clearly yet. Sappey has investigated lymphatic drainage of breast in 1874, observed that the lymph of the breast collected in a subareolar plexus and then drained towards the axilla through lymph collection vessels [
3,
4]. Sappey’s description of breast lymphatic drainage has been universally accepted for nearly 100 years. However, in 1959 Turner-Warwick has found that the breast drained directly from the tumor to the axilla [
3,
5]. In our previous study [
6], three types of sentinel lymphatic channels (SLCs) have been found, including superficial sentinel lymphatic channels (SSLCs), penetrating sentinel lymphatic channels (PSLCs), and deep sentinel lymphatic channels (DSLCs). SSLCs originate from the subareolar lymphatic plexus and pass within the subcutaneous fatty tissue; PSLCs originate from the subareolar lymphatic plexus and penetrate through the breast parenchyma; DSLCs originate from parenchyma and pass through the breast parenchyma or within the retromammary cellular space. Therefore, based on these three types of SLCs, varied lymphatic drainage patterns (LDPs) could be formed draining the breast to the axilla, which could make an influence on the accuracy of SLNB [
6].
Based on previous studies [
3‐
5] and our own findings about SLCs [
6], the number of SLCs and SLNs are varied among breast cancer patients, which can partly explain why the number of SLNs is an important factor which would affect the accuracy of SLNB [
7‐
9]. Surgeons with little experience may miss some SLNs during the surgery [
10]. So, evaluating the SLCs and SLNs preoperatively could be of important significance. A large amount of studies have been conducted aiming at assessing SLNs preoperatively. The methods included computed tomography, magnetic resonance imaging, single-photon emission computed tomography, and fluorescence [
11‐
14]. Since Mattrey RF [
15] and his colleagues firstly applied contrast-enhanced ultrasound (CEUS) on SLN detection in breast cancer patients, it has been constantly studied because of its ease of use and cost effectiveness [
16‐
23]. In the study conducted by Sever AR and colleagues, SLCs and SLNs could be detected preoperatively with a high sensitivity [
23], allowing doctors to observe the enhancement of SLCs and SLNs in real time. They have found the existence of SLCs using CEUS, but the location and number of SLCs have not been reported, while the variation of SLCs among breast cancer patients would make an influence on the accuracy of SLNB [
3‐
6].
In this study, we aimed to assess the feasibility of evaluating the variation of SLCs and SLNs preoperatively using CEUS in order to improve the accuracy of SLNB.
Methods
Patient enrollment
Between November 2015 and December 2016, 46 consecutive patients were recruited into the study prospectively. Inclusion criteria included (1) invasive breast cancer diagnosed by core biopsy, (2) no axillary lymph node involvement by physical examination, and (3) patients went to undergo modified radical mastectomy. Exclusion criteria included (1) multiple tumor, (2) preoperative chemotherapy, (3) previous axillary node dissection, and (4) severe medical comorbidities
CEUS examination
CEUS was performed to the enrolled patients by two experienced sonographers (Gong H, Li C) using a MyLab™ Twice scanner (Esaote, Genoa, Italy). A high frequency linear-array probe (LA522) was used. Low mechanical index values were applied (0.05) to reduce the destruction of a contrast agent. A gray-scale ultrasound examination of the axilla was carried out before the injection of the contrast agent. The microbubbles (SonoVue™ BRACCO Imaging, S.p.A, Milan, Italy) used as a contrast agent was reconstituted with 3 ml of saline (NaCl 0.9%). Using a 25-G needle for local anesthesia, 3 ml of 2% lidocaine was injected into the subcutaneous layer of the areola. Using a tuberculin syringe with a 25-GA 5/8 needle, 1 ml of the reconstituted microbubbles was injected intradermally into the skin immediately adjacent to the mammary papillae [
21]. The infiltration of microbubbles into the SSLC/PSLC and the superficial sentinel lymph nodes (SSLNs)/penetrating sentinel lymph nodes (PSLNs) could be observed dynamically on CEUS. After the contrast agent drained out, 2 ml of microbubbles was injected into a single area of the peritumoral parenchyma approaching the axilla. The infiltration of microbubbles into the DSLC and the deep sentinel lymph nodes (DSLNs) could also be observed dynamically on CEUS. Immediately after the examination, all the enhanced SLNs were marked with a titanium clip (BARD, Ultra CLIP, San Geronimo, Humacao, USA) under the ultrasound guidance. After the titanium clip was inserted, gray-scale ultrasound examination was conducted to confirm the position of the clip, which was shown with high-echo.
Dissection of the excised specimen after surgery and pathological analysis
Under general anesthesia, 2 ml of blue dye was injected in the same site as microbubbles have been injected. The injection site was massaged for 5 min before the modified radical mastectomy. After the surgery, the excised specimen was examined carefully and all the dyed SLCs were dissected. Then, all the axillary lymph nodes (ALNs) underwent an X-ray examination to identify the titanium clip-marked SLNs which were enhanced on CEUS. If the titanium clip-marked SLNs found by X-ray examination were also dyed, it meant that the CEUS examination and blue dye came with the same result. All blue dyed SLNs, titanium clip-marked SLNs, and other ALNs were sent to the pathology laboratory for further histopathological analysis. If any suspicious cells were noted, immunohistochemical staining for cytokeratin was applied.
Statistical analysis
Mean, ratio, and range were analyzed for continuous variables. An actual LDP was defined on the combination of both CEUS and blue dye findings. The accuracy of CEUS on LDP assessment was determined as the ratio of the number of patients in which the LDP defined by CEUS coincided with actual LDP to the number of total participants.
Discussion
In this study, we detected three types of SLCs and five LDPs using CEUS. The detection rate of SLC was 46/46, and the accuracy was 43/46. For all the 3 inconsistent cases, DSLCs were missed. It may be due to the size of microbubbles and the less lymph capillaries in the parenchyma [
24]. The contrast microbubbles are encapsulated gas bubbles smaller than red blood cells with a diameter range 0.7–10 μm [
16], which is larger than the endothelial gap. So, sufficient massage is needed after the injection of microbubbles. Moreover, a new contrast agent with a smaller size may improve the detection accuracy of CEUS.
Robert F [
15] and his colleagues first applied microbubbles on SLN detection in breast cancer patients. They found that the infiltration of lymphatic channels could be observed in real time after the subcutaneous injection of a contrast agent. Another study conducted by Sever AR [
23] reported that the sensitivity of CEUS on SLN detection was 96%. They noticed the existence of SLCs, but the location and number of SLCs were not reported. In this study, three types of SLCs and five LDPs were detected by CEUS successfully, including SSLC, PSLC, SSLC + PSLC, SSLC + DSLC, and SSLC + PSLC + DSLC. The detection rate was 46/46. The accuracy was 43/46. In previous studies, the number of SLNs was 1 or 2 when the contrast agent was injected in the areola area only [
15‐
23]. In this study, 4 patients were found with 3–4 SLNs. This may result from the variation of SLCs as more than one SLC existed and some were bifurcated. This result suggests that CEUS may be a feasible way to assess the number of SLNs preoperatively.
The SLC was found bifurcated in 8 patients. Two branches drained to two different SLNs. In some cases, the SLN of each branch was located closely; otherwise, they could be spatially far apart, one of the SLNs may be located superficially while the other one is located quite deep in the axilla. In this situation, it may be with a high possibility to miss one of the two SLNs during the SLNB. So, using CEUS to assess the SLC and SLN preoperatively may be of important significance.
A discontinuous SLC was found in three cases, metastatic ALNs were found in all these cases. In two of these cases, the SLCs were also discontinuously dyed, and the corresponding SLNs were not dyed, either. This may partly explain the false negative result of SLNB using blue dye. Same result was also obtained by Goldberg when administrating microbubbles in a melanoma tumor animal model [
25]. We presumed that the SLC is embolized by tumor cells. So, SLNB is not suggested in this situation as it may lead to a false negative result.
Our study has some limitations. First, studies with more participants should be conducted to assess the impact of CEUS examination on a false negative rate of SLNB. Second, the titanium clips used for marking the enhanced SLNs were too small to be viewed or touched intraoperatively, which may cause difficulties in clinical application, whereas a guidewire may be of practical value.
Conclusion
CEUS is feasible to assess the variation of SLCs and SLNs preoperatively in early breast cancer patients. A discontinuous SLC and non-enhanced SLN on CEUS may be a sign of SLN metastasis, SLNB is not suggested in this situation. Clinical studies with more participants are still needed to confirm our findings. A new contrast agent with a smaller size and better enhanced effect could be developed to improve the detection accuracy of CEUS.
Acknowledgements
Not applicable.
Ethics approval and consent to participate
This retrospective study was approved by the ethics committee of The First Affiliated Hospital with Nanjing Medical University. Written consent was given by the patients for their information to be stored in the hospital database and used for research. This study was also in compliance with the Helsinki Declaration.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.